What is FEMSelect?
FEMSelect specializes in EnPlace, a minimally invasive treatment designed for Pelvic Organ Prolapse, a condition affecting many women over 50. The EnPlace procedure, which is FDA-cleared, offers the advantage of same-day treatment, facilitating a swift return to daily activities for patients. The company is dedicated to raising awareness and providing comprehensive resources for both patients and medical professionals regarding the symptoms and management of Pelvic Organ Prolapse. By focusing on restoring quality of life, FEMSelect is positioning itself as a key player in the women's health technology sector, offering innovative solutions to a widespread health concern.
How much funding has FEMSelect raised?
FEMSelect has raised a total of $9M across 1 funding round:
Series B
$9M
Series B (2022): $9M with participation from New Age Ventures, Mid Atlantic Bio Angels, Robin Hood Ventures, Triventures, and MEDA Angels
Key Investors in FEMSelect
New Age Ventures
New Age Ventures is a venture studio investing in diverse sectors including healthcare and digital health, focusing on pre-seed to Series B startups. They provide resources to exceptional teams throughout the venture lifecycle.
Mid Atlantic Bio Angels
Mid Atlantic Bio Angels is an angel investor group dedicated to investing in emerging life science companies globally, offering funding and feedback sessions for entrepreneurs.
Robin Hood Ventures
Robin Hood Ventures is a leading angel investment group specializing in early-stage, high-growth startups, providing capital and guidance across various industries including Life Sciences.
What's next for FEMSelect?
With its recent Series B financing, FEMSelect is poised for accelerated growth and market penetration. The company's strategic focus will likely involve expanding its sales and marketing efforts to reach a broader patient demographic and healthcare provider network. Further investment may also be directed towards research and development to enhance the EnPlace system or explore adjacent therapeutic areas within women's health. The sustained backing from prominent investors suggests a clear path towards commercial expansion and solidifying FEMSelect's position as a leader in minimally invasive gynecological treatments.
See full FEMSelect company page
